Cover Image

慢性阻塞性肺病:關鍵意見領袖 (KOL) 的考察

Chronic Obstructive Pulmonary Disorder (COPD): KOL Insight

出版商 FirstWord 商品編碼 330351
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
Back to Top
慢性阻塞性肺病:關鍵意見領袖 (KOL) 的考察 Chronic Obstructive Pulmonary Disorder (COPD): KOL Insight
出版日期: 2015年04月20日 內容資訊: 英文

在慢性阻塞性肺病的治療中,聯合治療正逐漸成為中心,GlaxoSmithKline (GSK)、Boehringer Ingelheim、AstraZeneca等企業互相競爭市場上的地位與佔有率。

本報告提供慢性阻塞性肺病的治療藥的美國及歐洲12名關鍵意見領袖 (KOL) 的各種見解彙整。


  • LAMA:Spiriva (Boehringer Ingelheim)、Eklira/Tudorzas (AstraZeneca)、Seebri (Novartis)、Incruse (GSK)
  • LABA:Arcapta/Onbrez (Novartis)、Striverdi (Boehringer Ingelheim)
  • LAMA/LABA並用:Ultibro (Novartis)、Anoro (GSK)、Duaklir (AstraZeneca)
  • ICS/LABA並用:Seretide/Advair (GSK)、Revlar/Breo (GSK)、Symbicort (AstraZeneca)
  • PDEIV抑制劑:Daliresp/Daxas (武田藥品工業)
  • 慢性阻塞性肺病的研發產品線:ICS/LABA/LAMA3劑並用、ICS/LAMA並用、抗IL5單株抗體、PI3k抑制劑、MAPK抑制劑、MABA
Product Code: 596200354

Combination therapy is set to take centre stage in the treatment of COPD as leading companies such as GlaxoSmithKline (GSK), Boehringer Ingelheim and AstraZeneca vie for market position and share. But will clinicians, payers and patients be persuaded to change from well-established products?

Despite recently approved dual combinations of Long Acting Muscarinic Antagonists (LAMA) and Long Acting Beta2 Agonists (LABA) bringing little novelty to the therapeutic party, companies remained focused on combination approaches. The focus now is on triple combination products, with companies arguing that these will simplify treatment sequencing and provide adherence benefits. But do KOLs agree?

Chronic Obstructive Pulmonary Disorder (COPD): KOL Insight provides answers to this question, plus many more. It includes insight and opinion from 12 leading US and European KOLs, presents business-critical insights for branded pharma and the drug discovery community, and highlights what KOLS think about current treatments, and what new therapies will need to demonstrate for the COPD treatment paradigm to change.

KOL Views Covered

  • LAMAs: Spiriva (Boehringer Ingelheim), Eklira/Tudorzas (AstraZeneca), Seebri (Novartis), Incruse (GSK)
  • LABAs: Arcapta/Onbrez (Novartis), Striverdi (Boehringer Ingelheim)
  • LAMA/LABA combinations: Ultibro (Novartis), Anoro (GSK), Duaklir (AstraZeneca)
  • ICS/LABA combinations, including Seretide/Advair (GSK), Revlar/Breo (GSK), Symbicort (AstraZeneca)
  • Phosphodiesterase-IV inhibitors, including Daliresp/Daxas (Takeda)
  • COPD R&D Pipeline: Triple ICS/LABA/LAMA combinations, ICS/LAMA combinations, Anti-IL5 mAbs, PI3K inhibitors, MAPK inhibitors and MABAs

Key Benefits

  • Know the opinions of KOLs and formulate effective strategies for product positioning and clinician communication
  • Map new treatment options to COPD patients and patient sub-groups
  • Identify product attributes and patient characteristics that the KOLs think are the most important in terms of prescribing decisions
  • Discover which clinical trials the KOLs believe will have a significant impact on future treatment decisions and their likely outcomes
  • Evaluate the changing and challenging competitive landscape

Gain Answers to Key Questions

  • Where next for Boehringer Ingelheim's blockbuster LAMA Spiriva (tiotropium) when it comes under pressure from combination products?
  • Patient enthusiasm for specific inhaler devices influences prescribing: which are favoured and what are the influences?
  • What positive outcome from the SUMMIT clinical trial could provide a competitive advantage for GSK's Revlar/Breo combination?
  • How might AstraZeneca exploit positive views of its Genuair/Pressair DPI device for Eklira/Tudorza?
  • Novartis (Ultibro), GSK (Anoro) and AstraZeneca's Duaklir are locked in battle in the LAMA/LABA sector with Boehringer Ingelheim set to join the fray; but do clinicians see real benefits and what clinical trials could alter perceptions?
  • What are the prospects for developmental anti-IL5 antibodies, MABAs, PI3K inhibitors and MAPK inhibitors and how do clinicians view them?

Top Takeaways

  • Know the detailed opinions of leading front line clinicians on current and late stage COPD therapies and what they see as the critical advantages/disadvantages affecting their decision to prescribe
  • Appreciate the important factors affecting the COPD sector and identify key areas for strategic and tactical action
  • Understand how new combination therapies will fit into the treatment paradigm and identify the products that will be adversely affected
  • Review KOL attitudes to important clinical trials such as ATTAIN, ACCORD, GLOW, INVIGORATE, SPARK, ILLUMINATE, FLAME, ACLIFORM, AUGMENT COPD, TONADO 1&2 and SUMMIT

Key Opinion Leaders

  • KOLs from US
    • Dr Nick Gross, Volunteer Attending Physician, St Francis Hospital, Hartford, CT Professor Richard Casaburi, Professor of Medicine and Associate Chief for Research, Division of Respiratory Medicine, Harbor-UCLA Medical Center, Torrance, California
    • Dr Barry Make, Professor of Medicine, Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado School of Medicine, Denver, CO
    • Dr Donald P. Tashkin, Emeritus Professor of Medicine, Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine, University of California Los Angeles
    • Dr Edward Eden, Associate Professor of Clinical Medicine, Columbia University College of Physicians and Surgeons, New York
    • Professor Christopher Cooper, Professor of Medicine and Physiology, David Geffen School of Medicine, University of California, Los Angeles
  • KOLs from Europe
    • Professor Nicolas Roche, Professor, Respiratory Medicine, Paris Descartes University; Department of Respiratory and Intensive Care Medicine, Cochin-Broca-Hôtel-Dieu Hospital Group; Researcher, Paris Descartes University, France
    • Dr Lipworth, Head, Asthma and Allergy Research Group; Professor, Allergy and Pulmonology at Ninewells Hospital and Medical School, University of Dundee, UK
    • Professor Peter Barnes, Professor of Thoracic Medicine, National Heart and Lung Institute; Head of Respiratory Medicine, Imperial College; Honorary Consultant Physician, Royal Brompton Hospital, London, UK
    • Dr Rene Aalbers, Consultant Physician, Respiratory Medicine at Martini Hospital, Groningen, The Netherlands
    • Anonymous KOL, Germany
    • Anonymous KOL, Germany

Update Bulletins Offer Ongoing Benefits

The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord's guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.

  • Your Therapy Trends Report purchase entitles you to receive three Update Bulletins, which are published approximately every three months for 12 months following the report's publication date, April 2015.
  • You will receive a copy of each Update Bulletin once available, which are issued each quarter after the publication date.
Back to Top